In a 78-year-old man with an elevated prostate-specific antigen (PSA) of 8.3 ng/mL, PSA density of 0.17 ng/mL², prostate MRI showing PIRADS 2, and a 2.9 × 2.3 cm hypo‑enhancing lesion in the right hemiscrotum, what is the appropriate work‑up and treatment?

Urgent Urologic Referral for Scrotal Mass Evaluation and Prostate Cancer Risk Assessment

This 78-year-old man requires immediate urologic referral for two distinct concerns: (1) evaluation of the 2.9 × 2.3 cm hypo-enhancing scrotal mass, which takes priority given its size and imaging characteristics, and (2) consideration of prostate biopsy given his PSA of 8.3 ng/mL despite the reassuring PIRADS 2 and PSA density of 0.17 ng/mL/mL.

Primary Concern: Scrotal Mass

The 2.9 × 2.3 cm hypo-enhancing abnormality in the right hemiscrotum is the most urgent finding requiring immediate attention.

Immediate workup:

• Scrotal ultrasound with Doppler is the first-line imaging modality for any palpable scrotal abnormality 1
• This will characterize whether the mass is intratesticular (concerning for malignancy) versus extratesticular (more likely benign)
• Assess vascularity, echogenicity, and relationship to surrounding structures

Key differential considerations:

• Testicular tumor (if intratesticular)
• Epididymal mass
• Hydrocele or spermatocele
• Hernia contents
• Lipoma or other benign soft tissue mass

The hypo-enhancing characteristic on MRI raises concern but requires correlation with dedicated scrotal imaging. Urgent urologic consultation is mandatory regardless of ultrasound findings given the size and imaging characteristics 1.

Secondary Concern: Elevated PSA with Low-Risk MRI

Risk Stratification Analysis

Your patient's prostate parameters suggest intermediate-risk features by PSA alone but reassuring imaging:

• PSA 8.3 ng/mL exceeds the traditional 4.0 ng/mL threshold for biopsy consideration 2
• PSA density 0.17 ng/mL/mL is above the 0.15 ng/mL/mL threshold commonly used to identify higher-risk disease 3, 4
• PIRADS 2 indicates very low probability of clinically significant prostate cancer
• Age 78 years places him in a population where screening benefits are questionable 5

Prostate Biopsy Decision

The combination of PIRADS 2 with PSA density 0.17 ng/mL/mL creates clinical equipoise, but at age 78, the balance tips against routine biopsy.

Here's the algorithmic approach:

Arguments AGAINST immediate biopsy:

• PIRADS 2 lesions have very low rates of clinically significant prostate cancer (post-test probability approximately 6% with PSAD <0.15, and only marginally higher at 0.17) 3
• At age 78, life expectancy considerations become paramount—most guidelines suggest limited benefit from PSA screening in men >75 years 5
• The elevated PSA may reflect benign prostatic hyperplasia given the low PIRADS score
• Even if cancer is present, it's likely indolent given the imaging characteristics

Arguments FOR biopsy consideration:

• PSA 8.3 ng/mL is substantially elevated (>2× the 4.0 ng/mL threshold) 2
• PSAD 0.17 exceeds the 0.15 ng/mL/mL threshold associated with higher cancer risk 3, 4
• Some studies suggest PSAD ≥0.15 in PIRADS ≤2 lesions warrants consideration of biopsy 6
• Family history or African ancestry (if present) would increase risk

Recommended Approach

For the prostate concern, I recommend shared decision-making with the following framework:

1. If the patient has >10-year life expectancy and strong preference for definitive diagnosis:

   • Proceed with systematic 12-core TRUS-guided biopsy (targeted biopsy not indicated for PIRADS 2)
   • Accept that approximately 1 in 3 men with PSA >4.0 ng/mL have prostate cancer 5
   • Acknowledge that most detected cancers at this PSA/PIRADS combination would likely be low-grade

2. If the patient has <10-year life expectancy or prefers conservative management (recommended at age 78):

   • Defer biopsy and implement PSA surveillance
   • Repeat PSA in 3-6 months
   • Consider biopsy only if PSA rises by >1.0 ng/mL in one year or >1.5 ng/mL over two years 2
   • Repeat MRI if PSA continues rising to reassess for interval change

3. Additional risk stratification to inform decision:

   • Obtain free PSA if not already done (free/total PSA <10% increases cancer probability)
   • Document family history of prostate cancer
   • Assess comorbidities and estimated life expectancy
   • Consider 4Kscore or other biomarkers if available to refine risk

Critical Pitfalls to Avoid

1. Do not delay scrotal mass evaluation while focusing on the prostate—the scrotal finding requires urgent attention and may represent a more immediately concerning pathology

2. Do not assume the elevated PSA is solely from prostate cancer—at age 78 with PIRADS 2, benign prostatic hyperplasia is a likely contributor

3. Do not perform prostate biopsy without discussing life expectancy and treatment implications—detecting low-grade cancer in a 78-year-old may lead to overtreatment without mortality benefit

4. Do not use PIRADS 2 as absolute reassurance—while negative predictive value is high, approximately 10-15% of clinically significant cancers can be missed, particularly with anterior tumors 7

5. If biopsy is performed, ensure adequate anterior zone sampling—men with elevated PSA but low-grade disease on standard biopsy may harbor anterior tumors 7

Monitoring Plan if Biopsy Deferred

• PSA every 3-6 months for the first year, then annually if stable 2
• Digital rectal examination at each visit
• Repeat MRI in 12-24 months if PSA remains elevated or rises
• Urologic consultation if PSA velocity >1.0 ng/mL/year or DRE changes 2

The scrotal mass takes absolute priority and requires urgent urologic evaluation with scrotal ultrasound. The prostate concern, while requiring attention, should be addressed through shared decision-making that heavily weighs the patient's age, life expectancy, and values regarding cancer detection versus potential overtreatment.